In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on Meridian Bioscience (VIVO – Research Report), with a price target of $34.00. The company’s shares closed yesterday at $33.39.
According to TipRanks, Chen is an analyst with an average return of -33.1% and a 21.49% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Vaccitech Plc, and Bio-Path Holdings.
The word on The Street in general, suggests a Hold analyst consensus rating for Meridian Bioscience with a $34.00 average price target.
See today’s best-performing stocks on TipRanks >>
VIVO market cap is currently $1.46B and has a P/E ratio of 34.88.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
Read More on VIVO:
